Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Hepatic Pharmacology

Therapeutic effect of osthole on hyperlipidemic fatty liver in rats



To study the effects of osthole on hyperlipidemic fatty liver and investigate the possible mechanisms.


A rat model with hyperlipidemic fatty liver was successfully established by feeding fatty milk for 6 weeks. The experimental rats were then treated with 5-20 mg/kg osthole for 6 weeks. The mouse hyperlipidemic model was induced by feeding fatty milk when they were treated with 10-20 mg/kg osthole for 3 weeks.


After treatment with osthole, the levels of rat serum total cholesterol (TC), triglyceride (TG) and low density lipoprotein-cholesterol significantly decreased as compared with the fatty liver model group (P<0.05 or P<0.01). Hepatic weight and its coefficient, the hepatic tissue contents of TC, TG, and malondialdehyde, also significantly decreased (P<0.05 or P<0.01). In fatty milk-induced hyperlipidemic mice, the post-heparin plasma activities of lipo-protein lipase (LPL), hepatic lipase (HL), and total lipase (TL) significantly increased after treatment with 10-20 mg/kg osthole for 3 weeks (P<0.05 or P<0.01). Importantly, the histological evaluation of rat liver demonstrated that osthole dramatically decreased lipid accumulation (P<0.01).


Osthole was found to have therapeutic effects on fatty milk-induced rat fatty liver; the mechanisms might be associated with its anti-oxidation and the elevation of the activities of LPL and HL.


  1. Younossi ZM, Gramlich T, Liu YC, Matteoni C, Petrelli M, Goldblum J, et al. Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations. Mod Pathol 1998; 11: 560–5.

    CAS  PubMed  Google Scholar 

  2. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC . Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413–9.

    CAS  Article  Google Scholar 

  3. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134–40.

    Article  Google Scholar 

  4. Ryan MC, Wilson AM, Slavin J, Best JD, Jenkins AJ, Desmond PV . Associations between liver histology and severity of the metabolic syndrome in subjects with nonalcoholic fatty liver disease. Diabetes Care 2005; 28: 1222–4.

    Article  Google Scholar 

  5. Adams LA, Angulo P, Lindor KD . Nonalcoholic fatty liver disease. Can Med Assoc J 2005; 172: 899–905.

    Article  Google Scholar 

  6. Yang XH, Li SM, Ma FG . Study on the sterilization of Cnidium monnieri solution. Guangzhou Med J 1997; 28: 14–5. Chinese.

    CAS  Google Scholar 

  7. Basnet P, Yasuda I, Kumagai N, Tohda C, Nojima H, Kuraishi Y, et al. Inhibition of itch-scratch response by fruits of Cnidium monnieri in mice. Biol Pharm Bull 2001; 24: 1012–5.

    CAS  Article  Google Scholar 

  8. Liu JX, Zhang WP, Zhou L, Wang XR, Lian QS . Anti-inflammatory effect and mechanism of osthole in rats. J Chin Med Mater 2005; 28: 1002–6. Chinese.

    Google Scholar 

  9. Wang SH, An F, Zhang DS, Zhang L . Experiment study on anti-oxidation effect of osthole. Chin Tradit Patent Med 2005; 27: 488–9. Chinese.

    Google Scholar 

  10. Zhou J, Cheng WX, Xu YH . Experimental study on anti-tumour effect of osthole extracted from the fruits of Cnidium monnieri (L.) Cusson. Zhejiang J Integr Tradit West Med 2002; 12: 76–8. Chinese.

    Google Scholar 

  11. Okamoto T, Kawasaki T, Hino O . Osthole prevents anti-Fas antibody-induced hepatitis in mice by affecting the caspase-3-mediated apoptotic pathway. Biochem Pharmacol 2003; 65: 677–81.

    CAS  Article  Google Scholar 

  12. Yan M, Lu RJ, Jia XQ, Meng FL, Zhao XC . An experimental study on treating hyperlipidemic fatty liver with simvastain. Chin J Dig 2002; 22: 223–5. Chinese.

    Google Scholar 

  13. Ni HC, Li J, Jin Y, Zang HM, Peng L . The experimental animal model of hyperlipidemia and hyperlipidemic fatty live in rats. Chin Pharmacol Bull 2004; 20: 703–8. Chinese.

    Google Scholar 

  14. Tang Y, Tang ZZ, Yang L, Wang XK, Qiu W . Experimental study on treatment of fatty liver with hyperlipemia by xiao-zhi potion in rat model. Pharm J Chin PLA 2003; 6: 429–31. Chinese.

    Google Scholar 

  15. Cai BX, Xie ML, Gu ZL . The interactions of effective site clusters from Danshen and Shanzha on blood lipid of hyperlipidemic mice by orthogonal experimental design. Chin Tradit Herb Drugs 2004; 35: 192–4. Chinese.

    CAS  Google Scholar 

  16. Huang ZS, Wang ZW, Liu MP, Wu QG, Zhou L . Pharmacodynamic study on anti-fatty liver of hujin pills. Chin Tradit Patent Med 1998; 20: 27–8. Chinese.

    Google Scholar 

  17. Zhong L, Fan JG, Wang GL, Wu WQ, Jiang JM, Shi Q, et al. The establishment of nonalcoholic steatohepatitis (NASH) animal model. J Chin Prac Med 2000; 2: 3–6. Chinese.

    Google Scholar 

  18. Huang MA, Greenson JK, Chao C, Anderson L, Peterman D, Jacobson J, et al. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol 2005; 100: 1072–81.

    Article  Google Scholar 

  19. Angulo P . Non-alcoholic fatty liver disease. N Engl J Med 2002; 346: 1221–31.

    CAS  Article  Google Scholar 

  20. Bos G, Snijder MB, Nijpels G, Dekker JM, Stehouwer CD, Bouter LM, et al. Opposite contributions of trunk and leg fat mass with plasma lipase activities: the hoorn study. Obes Res 2005; 13: 1817–23.

    CAS  Article  Google Scholar 

  21. Merkel M, Heeren J, Dudeck W, Rinninger F, Radner H, Breslow JL, et al. Inactive lipoprotein lipase (LPL) alone increases selective cholesterol ester uptake in vivo, whereas in the presence of active LPL it also increases triglyceride hydrolysis and whole particle lipoprotein uptake. J Biol Chem 2002; 277: 7405–11.

    Article  Google Scholar 

  22. Schneider JG, von Eynatten, M, Schiekofer S, Nawroth PP, Dugi KA . Low plasma adiponectin levels are associated with increased hepatic lipase activity in vivo. Diabetes Care 2005; 28: 2181–6.

    CAS  Article  Google Scholar 

  23. Santamarina-Fojo S, Gonzalez-Navarro H, Freeman L, Wagner E, Nong Z . Hepatic lipase, lipoprotein metabolism, and atherogenesis. Arterioscl Throm Vas 2004; 24: 1750–4.

    CAS  Article  Google Scholar 

  24. Pessayre D, Berson A, Fromenty B, Mansouri A . Mitochondria in steatohepatitis. Semin Liver Dis 2001; 21: 57–69.

    CAS  Article  Google Scholar 

  25. Zeng MD . Pathogenesis and two “hits” hypothesis of fatty liver. Chin J Dig 2002; 22: 167–8. Chinese.

    Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Mei-lin Xie.

Additional information

Project supported by the “Three Medicines” tackle Key Problems in Science and Technology Foundation of Suzhou, China (No SSY0608)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Zhang, Y., Xie, Ml., Zhu, Lj. et al. Therapeutic effect of osthole on hyperlipidemic fatty liver in rats. Acta Pharmacol Sin 28, 398–403 (2007).

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI:


  • osthole
  • hyperlipidemic fatty liver
  • pharmacology

Further reading


Quick links